Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 56 results for "Victoza"

Novo Nordisk's Victoza combination trial shows positive results
Pharma Letter

Novo Nordisk's Victoza combination trial shows positive results

A combination of the Danish diabetes care giant Novo Nordisk's (NOV: N) Victoza (liraglutide), drug to treat type 2 diabetes, has demonstrated positive results, a trial has shown. The results of the trial for Victoza and lixisenatide (Sanofi's ... Pharma Letter, 3 weeks ago

18 images for Victoza

Pharma Letter, 3 weeks ago, 1 month ago, 1 month ago
Pharmafile, 1 month ago, 1 month ago
diaTribe, 1 month ago
One News Page United Kingdom, 1 month ago, 1 month ago
KABC Los Angeles, 3 months ago
ABC7, 3 months ago

Premarket Biotech Digest: Which Cancer Drug, MannKind's Future, Victoza Trial

Dr De's Opening Thoughts: Which company leads cancer sales in 2020? By 2020, according to consensus estimates , of the 20 top drugs in cancer, 7 will be from Roche (OTCQX:RHHBY), 2 each from Celgene (CELG) and Bristol Myers Squibb, and 1 each for ...
 TeleTrader.com1 month ago

Moving forward in diabetes

As many as 387 million people worldwide are living with diabetes, and it is predicted that by 2035 more than 10% of the world's adult population 592 million people worldwide will have diabetes. Yet the rule of halves means that only around 6% of ...
 Pharmafile6 days ago
Seeking Alpha

Revisiting NASH: Therapeutic Targets And The Competitive Landscape

Summary NASH is an exciting space set to be the next biotech breakout indication. We provide investors a detailed description of this complex disease and touch upon scientific concepts that aid in the understanding of the space. Finally, we ...
 Seeking Alpha1 week ago
BioPharma Dive

Sanofi hopes to broaden diabetes portfolio as FDA accepts lixisenatide submission

Dive Brief: Sanofi's lixiseantide is a once-daily, prandial GLP-1 receptor agonist,which is in the same class as drugs like Novo's Victoza (liraglutide) and Lilly's Trulicity (dulaglutide). The candidateis designed to increase GLP-1 production in ...
 BioPharma Dive1 week ago
Siasat Daily

Here`s how anti-diabetic drugs can help you with binge-eating

Washington D.C, Sept 30: As per a recent study, diabetes medication can help you reduce the food intake. The Sahlgrenska Academy study shows that medication used for type-2 diabetes, which mimics the gut-brain hormone glucagon-like peptide-1, can ...
 Siasat Daily1 week ago Diabetes medication can reduce food intake  Alpha Galileo2 weeks ago Diabetes Medication May Help Reduce Alcohol Depedence  Science World Report2 weeks ago
Seeking Alpha

Catalyst Packed Quarter Looming For Antares Pharma

Summary Antares has multiple catalysts that could move the stock in Q4 2015. The catalysts are listed and discussed. The risk/reward looks attractive. Every quarter I try to sit down and analyze each stock I hold for near-term ...
 Seeking Alpha2 weeks ago
Pharma Letter

FDA approves two new drugs for diabetes from Novo Nordisk

The US Food and Drug Administration on Friday approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus, both from Danish ...
 Pharma Letter2 weeks ago FDA: Diabetes Drugs Such as Januvia, Others Linked to Severe Joint Pain  Drug Watch1 month ago
European Pharmaceutical Review

Xultophy trial shows improvements in patient-reported outcomes

New findings from the DUAL V Phase 3b clinical trial showed greater improvements in treatment-related satisfaction and patient-reported physical health in people treated with Novo Nordisks Xultophy versus insulin glargine U100. The DUAL V trial ...
 European Pharmaceutical Review3 weeks ago New Xultophy (IDegLira) phase 3b trial shows improvements in patient-reported outcomes versus insulin glargine  Medical News Today3 weeks ago
BioPharma Dive

Merck's once-weekly diabetes med as effective as daily Januvia in study

Dive Brief: According to Merck's researchers, omarigliptin has the same efficacy and safety profile as Januvia (sitagliptin), based on the results of a 24-week study of 642 patients with type 2 diabetes. Merck is the biggest seller of oral drugs ...
 BioPharma Dive3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
Get updated on latest news & your favorite topics right in your inbox!
More     Less